In at least ten percent of asthma patients, there is an excessive symptom burden despite maximum controller therapy. A rational approach to treatment requires identifying one of three endotypes with distinct pathophysiology. Eosinophilic asthma, allergic asthma, and non-eosinophilic asthma can be differentiated by markers in blood and sputum. And targeted therapies have emerged, such as monoclonal antibodies to stages in the cytokine pathway that underlies eosinophil recruitment. It’s also important to consider the co-morbidities and risk factors that contribute to the disease, and to coordinate therapy in a multi-disciplinary way.
Guests: Professor Peter Gibson FRACP (Hunter Medical Research Institute, University of Newcastle), Professor Vanessa McDonald FRCNA (Hunter Medical Research Institute, University of Newcastle). Links to resources mentioned in the podcast are provided on the RACP website.[Case Report] 68yo with cardiometabolic risk factors and transient monocular vision loss
[Journal Club] Baricitinib immune therapy for new onset type 1 diabetes
Ep106: The whiskey fix and the apple of Granada
Ep105: When parents and paediatrics clash
[IMJ On-Air] Is the jury still out on omega-3 supplementation?
[IMJ On-Air] HepatoCare: a model for palliative and supportive care in advanced cirrhosis
Ep102: Staying on script with semaglutide
Ep101: Setting the standard for workforce wellbeing
Ep100: Conversations with ChatGPT
Ep99: When AI goes wrong
[IMJ On-Air] A tiger in the mallee: Victoria’s JEV cluster
Ep97: The governance of AI
Ep96: The ergonomics of AI
Ep95: Machine Learning 101
Ep94: Facing up to racial bias
Ep93: The rise and fall of mpox
Ep92: Data-driven practice improvement
[IMJ On-Air] Hyperglycaemia and COVID-19
[IMJ On-Air] High readmission rates in cirrhotic patients
Ep89: What we know about long COVID
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.